Stock Market Reviews

ENTA (Enanta Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on ENTA (Enanta Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
  WATERTOWN, Mass., October 01, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of custom
  Oct 1, 2025 - $ENTA
• Enanta stock doubles despite RSV trial missing primary endpoint
  Enanta is advancing zelicapavir to Phase III trials after CMO Dr Scott Rottinghaus said it is justified by the Phase IIb data.
  Sep 30, 2025 - $ENTA
• Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
  WATERTOWN, Mass., September 30, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its co
  Sep 30, 2025 - $ENTA
• Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults
  Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or asthma. Zelicapavir, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is a novel N-protein inhibitor in devel
  Sep 29, 2025 - $ENTA
• Enanta Pharmaceuticals Says Zelicapavir Misses Phase 2 Primary Endpoint, But Shows RSV Improvement
  Enanta Pharmaceuticals (ENTA) said Monday data from its phase 2 trial of zelicapavir, an oral antivi
  Sep 29, 2025 - $ENTA
• Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
  WATERTOWN, Mass., September 29, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those wit
  Sep 29, 2025 - $ENTA
• Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
  WATERTOWN, Mass., September 26, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.
  Sep 26, 2025 - $ENTA
• Enanta CFO dies after taking medical leave of absence
  Harry R. Trout was named interim finance chief of the drug company in late August as long-time CFO Paul J. Mellett, Jr. went on medical leave.
  Sep 3, 2025 - $ENTA
• Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
  WATERTOWN, Mass., September 03, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
  Sep 3, 2025 - $ENTA
• Does Enanta’s EU Lawsuit Over Paxlovid Shift the Bull Case for Pfizer (PFE)?
  Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer and subsidiaries in the Unified Patent Court of the European Union, alleging that Pfizer’s COVID-19 antiviral Paxlovid infringes newly granted European Patent No. EP 4 051 265 across 18 EU countries. This legal challenge introduces significant uncertainty around a key revenue driver for Pfizer and comes as investor attention remains elevated due to both fundamental performance and shifting sentiment...
  Aug 28, 2025 - $ENTA